VivoSeq
Dermatology

Pruritus

89

Pipeline Programs↗

14

Active Trials↗

50

Companies Involved↗

Pruritus is a moderately active landscape with 89 programs across 50 companies. The most active players are Kamari Pharma Ltd, Escient Pharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd.. 25 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kamari Pharma Ltd

1 program

Phase 1E

Escient Pharmaceuticals, Inc

1 program

Phase 1K

Kissei Pharmaceutical Co., Ltd.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2K

Keymed Biosciences Co.Ltd

1 program

Phase 2P

Patara Pharma

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical14

Alcohol

Astellas

Bilastine

Menarini International Operations Luxembourg SA

Nemolizumab

Roche

Senna

Medtronic - MITG

Montelukast

Organon and Co

Phase 18

Midazolam

Conrado Roberto Hoffmann Filho

Lidocaine IV

Kasr El Aini Hospital

Xiao-Feng-San+shian-Fang-Hwa-Ming-Yiin

Chang Gung Memorial Hospital

TRK-820

Toray Industries, Inc

IMP Application KM-001

Kamari Pharma Ltd

Phase 229

Ketamine Hydrochloride

Boehringer Ingelheim

Desloratadine

Organon and Co

Naloxone

Scienture

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Itacitinib

Incyte

Phase 313

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Colesevelam

Cosette Pharmaceuticals, Inc.

CR845

Cara Therapeutics, Inc.

Nabilone

Bausch Health Americas, Inc.

Hydroxyzine

Pfizer

Approved25

Thalidomide

Bristol-Myers Squibb

Loratadine

Perrigo Company

Ondansetron

Novartis

Cetirizine

Kenvue Brands

Clotrimazole

Bayer

Analysis

Modality Breakdown

98%

Small molecule

96 of 98 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody22%

Small molecule leads; the ring shows all 98 classified programs, each share of the total. Modality classified for 98% of 101 pipeline programs.

Analysis

Trial Status

102

clinical trials

Completed61 · 60%
Unknown status15 · 15%
Recruiting10 · 10%
Terminated9 · 9%
Not yet recruiting4 · 4%
Withdrawn2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

102 trials

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Recruiting·VVifor Fresenius Medical Care Renal Pharma·Phase 2·NCT06593392·18 enrolled
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
Recruiting·UUniversity Hospital, Rouen·N/A·NCT05689463·100 enrolled
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
Recruiting·GGalderma R&D·Phase 2·NCT07074977·50 enrolled
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Recruiting·QQilu Pharmaceutical (Hainan) Co., Ltd.·Phase 3·NCT06446310·194 enrolled
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Recruiting·—·Phase 2·NCT06226610·46 enrolled
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
Recruiting·GGuangdong Provincial People's Hospital·N/A·NCT07098351·93 enrolled
Efficacy of Pregabalin for Diabetic Pruritus - A Randomized Controlled Study.
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT06790537·46 enrolled
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Recruiting·Sanofi logoSanofi·Phase 3·NCT05263206·284 enrolled
A Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
Recruiting·UUniversity of California, San Diego·Phase 2·NCT06748404·28 enrolled
Establishment of a Patient Library in Patients With Pruritus Sine Materia
Recruiting·UUniversity Hospital, Brest·N/A·NCT05678309·175 enrolled
The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus.
Not yet recruiting·—·Phase 2·NCT06579066·123 enrolled
Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients
Not yet recruiting·RRabin Medical Center·Phase 1·NCT06931119·30 enrolled
Effect of Propofol Administration Time on the Incidence and Severity of Intrathecal Morphine-induced Pruritus in Parturient Undergoing Elective Cesarean Delivaries
Not yet recruiting·—·Phase 4·NCT06715657·204 enrolled
Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study
Not yet recruiting·UUniversity Hospital, Brest·Phase 3·NCT06435299·218 enrolled
Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients
Completed·SSeoul National University Boramae Hospital·N/A·NCT03576235·80 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)